REUTERS: Novavax expects information from a late-stage US trial of its COVID-19 vaccine at the beginning of April, after which it’ll apply for emergency use authorisation, the drug developer’s R&D head Gregory Glenn mentioned on Wednesday (Fb 24).
“We predict outcomes proper at first of quarter two and shortly thereafter we can be submitting for EUA (in US),” he mentioned at a Washington Publish on-line occasion.
The Novavax government mentioned the vaccine has proven an ideal “security profile” in UK trials and the corporate would possibly ask the US Meals and Drug Administration to contemplate the UK information for vaccine authorisation.
On Monday, Novavax accomplished enrolling 30,000 volunteers within the late-stage research in america and Mexico.
The corporate mentioned final month its vaccine was 89.3per cent efficient in stopping COVID-19 in a trial performed in the UK.
It was practically as efficient towards the extra extremely contagious variant first found within the UK.